A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT)
combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer
Patients with newly diagnosed or progressing Brain Metastases.